Literature DB >> 2240996

[A cellular anti-ischemic agent, trimetazidine prevents the deleterious effects of oxygen free-radicals on the internal ear].

A Aubert1, C Bernard, P Clauser, C Harpey, H Vaudry.   

Abstract

Improvement of cochleovestibular symptoms induced by trimetazidine (TMZ) has been evidenced by clinical studies. However, a poor knowledge of the physiopathology and the scarcity of experimental models contributed to making determination of the mode of action of the drugs difficult. We studied the effect, in vitro, of TMZ on the production of oxygen-derived free radicals using, as a biological model, the isolated semicircular canal of the frog. This model allows to exert separate control over the ionic composition of the endo- and perilymphatic fluids. The spontaneous activity of the afferent nerve fibers, as well as the endolymphatic potential, were recorded at rest. Three additional parameters were analyzed, while the semicircular canal was subjected to mechanical stimulation, i.e., ampulla potential, nerve potential and the evoked frequency of action potentials. Free radical generation induced by the administration of phenazine methosulfate (PMS, 10(-5) M, 15 min) into the perilymphatic compartment, leads to a deterioration of the production of endolymph and the release of this afferent neuromediator. Inversely, PMS has no influence whatsoever on the mechanisms of mechanical-electrical transduction. The addition of TMZ (10(-6) or 10(-5) M) in the perilymphatic compartment counteracts the harmful effects of free radicals on the various bioelectric activities. These results suggest that the beneficial action of TMZ observed during treatment of cochleovestibular disorders is due, at least in part, to the anti-oxidizing properties of the molecule of interest.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2240996

Source DB:  PubMed          Journal:  Ann Otolaryngol Chir Cervicofac        ISSN: 0003-438X


  6 in total

1.  Comparison of cochlear cell death caused by cisplatin, alone and in combination with furosemide.

Authors:  Li Xia; Zhengnong Chen; Kaiming Su; Shankai Yin; Jian Wang
Journal:  Toxicol Pathol       Date:  2013-04-02       Impact factor: 1.902

2.  Targeting the mitochondrial trifunctional protein restrains tumor growth in oxidative lung carcinomas.

Authors:  Nivea Dias Amoedo; Saharnaz Sarlak; Emilie Obre; Pauline Esteves; Hugues Bégueret; Yann Kieffer; Benoît Rousseau; Alexis Dupis; Julien Izotte; Nadège Bellance; Laetitia Dard; Isabelle Redonnet-Vernhet; Giuseppe Punzi; Mariana Figueiredo Rodrigues; Elodie Dumon; Walid Mafhouf; Véronique Guyonnet-Dupérat; Lara Gales; Tony Palama; Floriant Bellvert; Nathalie Dugot-Senan; Stéphane Claverol; Jean-Marc Baste; Didier Lacombe; Hamid Reza Rezvani; Ciro Leonardo Pierri; Fatima Mechta-Grigoriou; Matthieu Thumerel; Rodrigue Rossignol
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

3.  Trimetazidine protects against hypoxia-reperfusion-induced cardiomyocyte apoptosis by increasing microRNA-21 expression.

Authors:  Qiong Yang; Kan Yang; An-Ying Li
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

4.  Effects of trimetazidine in acute pancreatitis induced by L-arginine.

Authors:  Akan Yenicerioglu; Ziya Cetinkaya; Mustafa Girgin; Bilal Ustundag; Ibrahim H Ozercan; Refik Ayten; Burhan H Kanat
Journal:  Can J Surg       Date:  2013-06       Impact factor: 2.089

5.  Clinical effects of carvedilol and trimetazidine for the treatmentof alcoholic myocardiopathy.

Authors:  Hui Li; Fu-Yuan Liu; Xiao-Lan Li; Xiao-Mei Li; Lei Zhu
Journal:  Exp Ther Med       Date:  2016-05-19       Impact factor: 2.447

6.  Evaluation of serum prolidase enzyme activity and oxidative stress in patients with tinnitus.

Authors:  Adnan Ekinci; Kaan Kamasak
Journal:  Braz J Otorhinolaryngol       Date:  2019-03-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.